BioRestorative Therapies Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de BioRestorative Therapies de 50.1% y 76.2% respectivamente, mientras que el BPA crecerá en un 47.1% al año.

Información clave

57.9%

Tasa de crecimiento de los beneficios

52.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	34.8%
Tasa de crecimiento de los ingresos	77.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	25 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:9OF - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3	-20	N/A	N/A	2
12/31/2025	3	-16	N/A	N/A	2
12/31/2024	1	-13	N/A	N/A	2
6/30/2024	0	-4	-7	-7	N/A
3/31/2024	0	-5	-6	-6	N/A
12/31/2023	0	-10	-7	-6	N/A
9/30/2023	0	-15	-7	-6	N/A
6/30/2023	0	-17	-7	-7	N/A
3/31/2023	0	-16	-7	-7	N/A
12/31/2022	0	-13	-6	-6	N/A
9/30/2022	0	-35	-6	-5	N/A
6/30/2022	0	-34	-5	-5	N/A
3/31/2022	0	-33	-4	-4	N/A
12/31/2021	0	-44	-3	-3	N/A
9/30/2021	0	-30	-3	-3	N/A
6/30/2021	0	-26	-3	-3	N/A
3/31/2021	0	-19	-2	-2	N/A
12/31/2020	0	-11	-2	-2	N/A
9/30/2020	0	-7	-3	-3	N/A
6/30/2020	0	-11	-4	-4	N/A
3/31/2020	0	-18	-5	-5	N/A
12/31/2019	0	-15	-7	-7	N/A
9/30/2019	0	-17	-7	-7	N/A
6/30/2019	0	-15	-6	-6	N/A
3/31/2019	0	-14	-6	-6	N/A
12/31/2018	0	-13	-5	-5	N/A
9/30/2018	0	-11	-5	-5	N/A
6/30/2018	0	-10	-4	-4	N/A
3/31/2018	0	-9	N/A	-4	N/A
12/31/2017	0	-9	N/A	-4	N/A
9/30/2017	0	-10	N/A	-4	N/A
6/30/2017	0	-9	N/A	-4	N/A
3/31/2017	0	-9	N/A	-5	N/A
12/31/2016	0	-9	N/A	-5	N/A
9/30/2016	0	-10	N/A	-5	N/A
6/30/2016	0	-9	N/A	-4	N/A
3/31/2016	0	-9	N/A	-4	N/A
12/31/2015	1	-8	N/A	-3	N/A
9/30/2015	1	-6	N/A	-3	N/A
6/30/2015	1	-6	N/A	-3	N/A
3/31/2015	1	-6	N/A	-3	N/A
12/31/2014	0	-6	N/A	-3	N/A
9/30/2014	0	-6	N/A	-3	N/A
6/30/2014	0	-6	N/A	-3	N/A
3/31/2014	0	-6	N/A	-3	N/A
12/31/2013	0	-6	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 9OF siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 9OF siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 9OF siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (76.2% al año) de 9OF crezcan más rápidamente que los del mercado German (5.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (76.2% al año) de 9OF crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 9OF se prevé que sea elevada dentro de 3 años.

BioRestorative Therapies Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2024

Recent updates

Second quarter 2024 earnings released: US$0.50 loss per share (vs US$0.77 loss in 2Q 2023)

BioRestorative Therapies, Inc., Annual General Meeting, Sep 19, 2024

BioRestorative Therapies, Inc. to Report Q2, 2024 Results on Aug 13, 2024

BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Full year 2023 earnings released: US$3.42 loss per share (vs US$5.11 loss in FY 2022)

New major risk - Shareholder dilution

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting

New major risk - Share price stability

BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Third quarter 2023 earnings released: US$0.64 loss per share (vs US$1.28 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.77 loss per share (vs US$1.29 loss in 2Q 2022)

BioRestorative Therapies, Inc., Annual General Meeting, Sep 13, 2023

Biorestorative Therapies Inc. Receives License from New York State

BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding

BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100

BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program

First quarter 2023 earnings released: US$1.53 loss per share (vs US$1.37 loss in 1Q 2022)

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial

Full year 2022 earnings released: US$5.11 loss per share (vs US$37.30 loss in FY 2021)

Biorestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to Its Thermostem(R) Program

BioRestorative Therapies Inc. Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem Targeting Polycystic Ovary Syndrome as an Indication

Third quarter 2022 earnings released: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc., Annual General Meeting, Nov 03, 2022

Second quarter 2022 earnings released: US$1.29 loss per share (vs US$5.11 loss in 2Q 2021)

BioRestorative Therapies, Inc. Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Biorestorative Therapies, Inc. Announces Clinical Trial Contract with Second Site for the Company’S Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (Cldd)

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

First quarter 2022 earnings released: US$1.37 loss per share (vs US$21.45 loss in 1Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc. Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Insider recently bought €240k worth of stock

Full year 2021 earnings released: US$37.30 loss per share (vs US$28.56 loss in FY 2020)

Biorestorative Therapies Announces It Has Initiated Its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

Forecast to breakeven in 2024

High number of new and inexperienced directors

BioRestorative Therapies, Inc. Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$4.99 loss per share (vs US$2.10 loss in 3Q 2020)

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento